Worth

The episode examines the ethics and economics of drug pricing through two case studies: Zaltrap, a $11,000/month cancer drug offering 42 additional days of life, and Sovaldi, a $84,000 hepatitis C cure with 95% efficacy. It presents data on insurance dynamics, out-of-pocket costs, and systemic strain, showing how high drug prices force rationing. Memorial Sloan Kettering’s public boycott of Zaltrap led to a 50% price cut, demonstrating rare institutional pushback.

It reveals how drug pricing decouples from medical value, with real-world data and institutional resistance that reshaped a pharmaceutical company’s pricing strategy.

1. 01Drug pricing often lacks correlation with clinical benefit—Zaltrap cost $11,000/month for a 42-day survival gain, double the price of an equally effective alternative.
2. 02Insurance structures amplify individual drug costs across populations: one $100,000 treatment depletes funds for 1,000 insured members.
3. 03High-efficacy, high-cost cures like Sovaldi ($84,000 for 12 weeks) force states to ration treatment based on disease severity, delaying care until patients are sicker.